Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine
Brand: PKU Sphere Liquid
PBAC's latest decision on Glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine: Recommended (2022). Considered for Dietary management of patients with phenylketonuria (PKU).
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Patients with phenylketonuria (PKU) requiring dietary management with a glycomacropeptide-based formula.
Therapy area
Metabolic
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
PKU Sphere20 Powder
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.